Skip Nav Destination
Issues
15 April 2007
-
Cover Image
Cover Image
Activated EGFR (red) and Ki67 (green) were expressed abundantly in head and neck carcinoma xenografts developed in nude mice. Cetuximab treatment caused more prolonged inhibition of EGFR, its downstream effectors STAT3 and BclXL, and the proliferation marker Ki67 compared with treatment with gefitinib. This resulted in a more potent tumor response to cetuximab compared with gefitinib in this model system. For further details, please see Feng et al. on page 2512 in this issue. - PDF Icon PDF LinkTable of Contents
ISSN 1078-0432
EISSN 1557-3265
Editorial
The Biology Behind
Molecular Pathways
Report from the FDA
Vorinostat for Treatment of Cutaneous Manifestations of Advanced Primary Cutaneous T-Cell Lymphoma
Bhupinder S. Mann; John R. Johnson; Kun He; Rajeshwari Sridhara; Sophia Abraham; Brian P. Booth; Leigh Verbois; David E. Morse; Josephine M. Jee; Sarah Pope; Ravi S. Harapanhalli; Ramzi Dagher; Ann Farrell; Robert Justice; Richard Pazdur
Human Cancer Biology
c-Kit/PDGFRA Gene Status Alterations Possibly Related to Primary Imatinib Resistance in Gastrointestinal Stromal Tumors
Francesca="C"> Miselli; Paola Casieri; Tiziana Negri; Marta Orsenigo; M. Stefania Lagonigro; Alessandro Gronchi; Marco Fiore; Paolo G. Casali; Rossella Bertulli; Antonino Carbone; Marco A. Pierotti; Elena Tamborini; Silvana Pilotti
Imaging, Diagnosis, Prognosis
Cancer Therapy: Clinical
Systemic Interleukin-2 and Adoptive Transfer of Lymphokine-Activated Killer Cells Improves Antibody-Dependent Cellular Cytotoxicity in Patients with Relapsed B-Cell Lymphoma Treated with Rituximab
Jesús G. Berdeja; Allan Hess; David M. Lucas; Paul O'Donnell; Richard F. Ambinder; Louis F. Diehl; Denise Carter-Brookins; Susan Newton; Ian W. Flinn
Cancer Therapy: Preclinical
Effect of Epidermal Growth Factor Receptor Inhibitor Class in the Treatment of Head and Neck Cancer with Concurrent Radiochemotherapy In vivo
Felix Y. Feng; Carlos A. Lopez; Daniel P. Normolle; Sooryanarayana Varambally; Xiaoxin Li; Patrick Y. Chun; Mary A. Davis; Theodore S. Lawrence; Mukesh K. Nyati
Cancer Prevention
Advertisement
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds